

# AMINOGLYCOSIDES TDM

DONE BY: SARA ALARFAJ

2014

# OUTLINE

- Introduction about Aminoglycosides.
- Spectrum/uses.
- TDM
- Aminoglycosides TDM
- Pharmacodynamics
- Pharmacokinetics.
- Dosing in AG.
- Sampling time and Monitoring.
- Toxicity
- Cases

# INTRODUCTION

- Aminoglycosides are widely used antibacterial agents, particularly for serious infections.
- They are bactericidal agents that inhibit protein synthesis.
- They have a narrow therapeutic index.

# SPECTRUM/USES

- Single treatment for gm-ve bacilli.
- Empiric therapy.
- Combination with another drug for specific gm+ve infections, like Endocarditis.
- Combination with  $\beta$ -lactams.
- Surgical prophylaxis.

# THERAPEUTIC DRUG MONITORING

To use drug concentrations to manage a patient's medication regimen and optimize the outcomes.



# WHEN DO WE NEED TDM?

Toxicity

Lack of response

Compliance assessment

Changes in dose regimen

Clinical state changes

Drug interactions


Efficacy

# TDM IN AMINOGLYCOSIDES

- Narrow therapeutic index.
- Guide and monitor any dosing regimens.
- Evaluate for efficacy.
- Evaluate for potential toxicity.

**Nephrotoxicity.**  
**Ototoxicity.**

# PHARMACODYNAMICS



**Conc.  
dependent  
killing**

**Post  
Antibiotic  
Effect**



# PHARMACOKINETICS

## Absorption:

- Poorly absorbed orally, given IV infusion or

## Distribution:

- Vd ranges from 0.2 -0.4 L/kg, and is increased in ascites conditions.
- High conc in urine, low in CSF, bile and bronchial secretions.

## Elimination:

- Almost 99% is excreted unchanged by glomerular filtration.
- Half life (1.5 to 3.5 hrs).

Cystic fibrosis Vd= 0.35  
L/kg  
Ascites Vd = 0.32 L/kg

Prolonged  
in neonates, infants  
and reduced renal  
function

# DOSING

Exclusions!

## Extended interval dosing (ODD):

- Concentration dependent antibiotics.
- Optimum bactericidal activity when conc 8 -10 times the MIC.
- 7 mg/kg q24hrs. (Genta, Tobra)

## Multiple daily dosing (traditional):

<u>CrCl</u>	<b>Dose (gentamicin, tobramycin)</b>
>60 ml/min	1.5-1.7 mg/kg/dose IV q8h
40-60 ml/min	1.2 - 1.5 mg/kg/dose IV q12h
20-40 ml/min	1.2-1.5 mg/kg/dose IV q12-24h
<20 ml/min	2 mg/kg loading dose

## Gram positive-synergy Dosing.

# CONT

- $IBW \text{ (males)} = 50 + (2.3 \times \text{inches above } 60 \text{ inches})$
- $IBW \text{, (females)} = 45 + (2.3 \times \text{inches above } 60 \text{ inches})$
- $ABW = IBW + [0.4 \times (TBW - IBW)]$

## Dosing :

- TBW in non-obese patients.
- AdjBW as the dosing weight in obese patients.
- Calculate CrCL with the Cockcroft-Gault equation.

## Loading Dose:

Site of infection or indication	Desired peak concentration	Loading dose, mg/kg
Uncomplicated lower urinary tract infection, gram-positive endocarditis, synergy with beta-lactams for serious gram-positive infections	2 to 4 $\mu\text{g/mL}$	0.6 to 1.2
Gram-negative sepsis or other serious gram-negative infections	6 to 8 $\mu\text{g/mL}$	2.5
Gram-negative pneumonia or acute life-threatening gram-negative infection in a critically ill patient	7 to 9 $\mu\text{g/mL}$	3.0

# CONT

## Maintenance Dose:

### A. Gentamicin & Tobramycin Initial Dosing

CrCL (mL/min)	High-Dose Extended-Interval* (Gentamicin/Tobramycin)	Conventional / Traditional (Gentamicin/Tobramycin)	Synergy** (Gentamicin/Tobramycin)
> 60	7 mg/kg Q24H	1.7 mg/kg Q8H	1 mg/kg Q8H
40-59	4 – 7 mg/kg Q36H	1.7 mg/kg Q12H	1 mg/kg Q12H
30-39	4 – 7 mg/kg Q48H	1.7 mg/kg Q24H	1 mg/kg Q24H
20-29	Not recommended	1.7 mg/kg Q24H	1 mg/kg Q24H
<20	Not recommended	2 mg/kg load, then dose by level	1 mg/kg load, then dose by level
Hemodialysis	Not recommended	2 mg/kg load, then 1.5 mg/kg post-HD	1 mg/kg q48-72H; consider redosing for pre-HD or post-HD Cp < 1mg/L
CRRT	Not recommended	1.5 – 2.5 mg/kg Q24-48H	1 mg/kg Q24H, then by level

\*See Hartford nomogram for monitoring of once-daily dosing regimens

\*\*Alternative for synergy: 3mg/kg Q24H for Streptococci and *Streptococcus bovis* endocarditis

### B. Amikacin Initial Dosing

CrCL (mL/min)	High-Dose Extended-Interval* (Amikacin)	Conventional / Traditional (Amikacin)
> 60	15 – 20 mg/kg Q24H	5 – 7.5 mg/kg Q8H
40-59	15 mg/kg Q36H	5 – 7.5 mg/kg Q12H
30-39	15 mg/kg Q48H	5 – 7.5 mg/kg Q24H
20-29	Not recommended	5 – 7.5 mg/kg Q24H
<20	Not recommended	5 mg/kg load, then dose by level
Hemodialysis	Not recommended	5 – 7.5 mg/kg post-HD
CRRT	Not recommended	10 mg/kg load, then 7.5 mg/kg Q24-48H

See Hartford nomogram for monitoring of once-daily dosing regimens- divide level by half then plot on graph

# SPECIAL POPULATIONS

population	dosing
<b>Neonates, children</b>	<b>0-7 days old:</b> 4-5 mg/kg/day. <b>Infants-children:</b> 5-7.5 mg/kg/day.
<b>Dialysis</b>	Supplemental doses of <a href="#">gentamicin</a> or <a href="#">tobramycin</a> of 1 to 2 mg/kg after each dialysis.
<b>CRRT</b>	LD= 2-3 mg/kg MD= 1-2 mg/kg q48-72 hrs. " serum conc"
<b>Cystic fibrosis</b>	7.5-10.5 mg/kg/day "divided q8hr"
<b>Burn patients</b>	Doses up to 7 to 8 mg/kg per day.
<b>Renal impairment "elderly"</b>	According to CrCL "mentioned before"

# SAMPLING TIME

- After three to five half-lives of the drug.
- Trough concentrations are measured within 30 minutes of the next dose.
- Peak concentrations within 30-60 minutes after the end of IV infusion, approximately 60 minutes after IM.

# LEVELS MONITORING

- Peak indicates efficacy.
- Trough indicates toxicity.

## Peak

Serious infections: 6-8  
mcg/mL

Life-threatening: 8-10  
mcg/mL

UTI: 4-6 mcg/ml

Synergy: 3-5 mcg/mL

## Trough

Serious infection: 0.5-1  
mcg/mL

Life-threatening: 1-2  
mcg/mL

Hospital acquired

pneumonia: <1 mcg/ml

# INTERPRETATION+ DOSE ADJUSTMENT

**Patient-specific  
pharmacokinetic  
parameters**

**Serum conc.  
levels**

**Optimal dose  
and frequency**



# TOXICITY AND MANA

- OD.
- Least toxic agent.
- Correct electrolyte imbalance.
- Careful with nephrotoxic agents.

Side effect	comments
Nephrotoxicity	<ul style="list-style-type: none"> <li>• Estimated by 10-20%.</li> <li>• ODD vs conventional dosing.</li> <li>• Management.</li> </ul>
Ototoxicity	<ul style="list-style-type: none"> <li>• Can be irreversible.</li> <li>• cochlear and vestibular toxicity and disequilibrium.</li> </ul>
Neuromuscular Blockade	<ul style="list-style-type: none"> <li>• Most patients have disease states or a drug therapy that interfere with neuromuscular transmission.</li> <li>• Myasthenia gravis is an absolute contraindication</li> </ul>

- Same as above
- Autometric testing
- Genetic screening
- Family history

# CASE 1

**A five years old female patient with a urinary tract infection being treated with Gentamicin 28 mg q 8hrs. She weighs 16 kg and 98 cm tall. Her serum Cr was 34. trough level came 0.4 mcg/L while peak level was 3 mcg/ml .. What's your recommendation ?**

- Keep the same dose/frequency.
- Switch to a OD dosing ( 7 mg/kg q 24= 112 mg q24)
- Increase dose on an 8 hourly frequency.

## CASE 2

- **A 55 years old male weighs 65 kg and 172 cm. Being treated with Tobramycin 110 mg q12 hrs (1.7 mg/kg) for Sepsis. Patient has serum Cr of 206, his peak level was 10 mcg/ml while trough level was 0.6 mcg/ml.. Your recommendations will be:**
- Hold dose, resample for another level.
- Decrease frequency to q 24 hrs with the same dose.
- Decrease dose and frequency.
- Do nothing.

THANK YOU

QUESTIONS?